
## **Dominic Oliver**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6664017/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry,the, 2020, 7, 611-627.	3.7	1,799
2	What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry, 2018, 17, 49-66.	4.8	387
3	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. European Psychiatry, 2017, 40, 65-75.	0.1	241
4	Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. Lancet Psychiatry,the, 2020, 7, 399-410.	3.7	182
5	Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology, 2020, 45, 1799-1806.	2.8	165
6	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. Schizophrenia Bulletin, 2020, 46, 110-120.	2.3	103
7	Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice. Schizophrenia Bulletin, 2021, 47, 284-297.	2.3	101
8	Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. Schizophrenia Bulletin, 2018, 44, 1362-1372.	2.3	100
9	Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2021, 78, 859.	6.0	96
10	Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. Schizophrenia Bulletin, 2019, 45, 562-570.	2.3	74
11	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. Microbial Biotechnology, 2020, 14, 741-750.	0.9	58
12	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 41, 28-39.	0.3	56
13	Why transition risk to psychosis is not declining at the OASIS ultra high risk service: The hidden role of stable pretest risk enrichment. Schizophrenia Research, 2018, 192, 385-390.	1.1	45
14	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. Frontiers in Psychiatry, 2019, 10, 174.	1.3	45
15	Are You on My Wavelength? Interpersonal Coordination in Dyadic Conversations. Journal of Nonverbal Behavior, 2020, 44, 63-83.	0.6	43
16	Lower speech connectedness linked to incidence of psychosis in people at clinical high risk. Schizophrenia Research, 2021, 228, 493-501.	1.1	40
17	Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): The need for refined prediction. European Psychiatry, 2018, 49, 62-68.	0.1	39
18	Real World Implementation of a Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk of Psychosis in Clinical Routine: Study Protocol. Frontiers in Psychiatry, 2019, 10, 109.	1.3	39

DOMINIC OLIVER

#	Article	IF	CITATIONS
19	Using Natural Language Processing on Electronic Health Records to Enhance Detection and Prediction of Psychosis Risk. Schizophrenia Bulletin, 2021, 47, 405-414.	2.3	36
20	Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. European Psychiatry, 2019, 57, 26-32.	0.1	34
21	Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. European Psychiatry, 2018, 52, 126-133.	0.1	32
22	A systematic review and metaâ€analysis of mental health service use in people who report psychotic experiences. Microbial Biotechnology, 2018, 12, 275-285.	0.9	30
23	Real-world implementation of precision psychiatry: Transdiagnostic risk calculator for the automatic detection of individuals at-risk of psychosis. Schizophrenia Research, 2021, 227, 52-60.	1.1	30
24	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Molecular Psychiatry, 2022, 27, 3510-3519.	4.1	29
25	Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis. Harvard Review of Psychiatry, 2021, 29, 196-215.	0.9	28
26	Natural Language Processing markers in first episode psychosis and people at clinical high-risk. Translational Psychiatry, 2021, 11, 630.	2.4	28
27	Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2018, 44, 264-275.	2.3	26
28	Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. Neuropsychopharmacology, 2019, 44, 1300-1309.	2.8	26
29	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 2021, 36, 100909.	3.2	25
30	Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack. Journal of Visualized Experiments, 2020, , .	0.2	19
31	Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology, 2022, 239, 1179-1190.	1.5	17
32	Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study. Translational Psychiatry, 2020, 10, 227.	2.4	16
33	Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. Translational Psychiatry, 2020, 10, 364.	2.4	15
34	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 3670-3678.	4.1	13
35	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. Schizophrenia Research, 2020, 226, 176-183.	1.1	11
36	Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. Translational Psychiatry, 2020, 10, 203.	2.4	10

DOMINIC OLIVER

#	Article	IF	CITATIONS
37	Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. Schizophrenia Research, 2021, 228, 403-409.	1.1	10
38	Real-World Implementation of Precision Psychiatry: A Systematic Review of Barriers and Facilitators. Brain Sciences, 2022, 12, 934.	1.1	10
39	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. European Neuropsychopharmacology, 2019, 29, 601-615.	0.3	8
40	Precuneus and insular hypoactivation during cognitive processing in first-episode psychosis: Systematic review and meta-analysis of fMRI studies. Revista De PsiquiatrÃa Y Salud Mental, 2022, 15, 101-116.	1.0	7
41	The role of parietal cortex in overimitation: a study with fNIRS. Social Neuroscience, 2018, 13, 214-225.	0.7	6
42	Development of the Korea-Polyenvironmental Risk Score for Psychosis. Psychiatry Investigation, 2022, 19, 197-206.	0.7	5
43	T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE. Schizophrenia Bulletin, 2020, 46, S268-S268.	2.3	4
44	The case for improved transdiagnostic detection of first-episode psychosis: Electronic health record cohort study. Schizophrenia Research, 2021, 228, 547-554.	1.1	3
45	How experimental cannabinoid studies will inform the standardized THC unit. Addiction, 2020, 115, 1217-1218.	1.7	2
46	T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. Schizophrenia Bulletin, 2018, 44, S162-S163.	2.3	0
47	F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?. Schizophrenia Bulletin, 2018, 44, S323-S323.	2.3	0
48	T139. OXYTOCIN ENHANCES NEURAL EFFICIENCY IN INFERRING OTHERS' SOCIAL EMOTIONS IN PEOPLE AT CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S283-S284.	2.3	0
49	M136. PSYCHOSIS POLYRISK SCORE (PPS): IMPROVING DETECTION OF INDIVIDUALS AT-RISK AND PREDICTION OF CLINICAL OUTCOMES. Schizophrenia Bulletin, 2020, 46, S187-S187.	2.3	0

50 Neurochemical models of psychosis risk and onset. , 2020, , 229-247.

0